Acevedo J; Acevedo ML; Gaete-Argel A; Araos R; Gonzalez C; Espinoza D; Rivas S; Pizarro P; Jarpa S; Soto-Rifo R; Jara A; Valiente-Echeverría F, 2022. Neutralizing antibodies induced by homologous and heterologous boosters in CoronaVac vaccines in Chile. Clin Microbiol Infect.
Soto JA; Melo-González F; Gutierrez-Vera C; Schultz BM; Berríos-Rojas RV; Rivera-Pérez D; Piña-Iturbe A; Hoppe-Elsholz G; Duarte LF; Vázquez Y; Moreno-Tapia D; Ríos M; Palacios PA; Garcia-Betancourt R; Santibañez Á; Pacheco GA; Mendez C; Andrade CA; Silva PH; Diethelm-Varela B; Astudillo P; Calvo M; Cárdenas A; González M; Goldsack M; Gutiérrez V; Potin M; Schilling A; Tapia LI; Twele L; Villena R; Grifoni A; Sette A; Weiskopf D; Fasce RA; Fernández J; Mora J; Ramírez E; Gaete-Argel A; Acevedo ML; Valiente-Echeverría F; Soto-Rifo R; Retamal-Díaz A; Muñoz-Jofré N; Meng X; Xin Q; Alarcón-Bustamante E; González-Aramundiz JV; Le Corre N; Álvarez-Figueroa MJ; González PA; Abarca K; Perret C; Carreño LJ; Bueno SM; Kalergis AM, 2022. Inactivated Vaccine-Induced SARS-CoV-2 Variant-Specific Immunity in Children. mBio 13(6):e0131122
Gálvez NMS; Pacheco GA; Schultz BM; Melo-González F; Soto JA; Duarte LF; González LA; Rivera-Pérez D; Ríos M; Berrios RV; Vázquez Y; Moreno-Tapia D; Vallejos OP; Andrade CA; Hoppe-Elsholz G; Iturriaga C; Urzua M; Navarrete MS; Rojas Á; Fasce R; Fernández J; Mora J; Ramírez E; Gaete-Argel A; Acevedo ML; Valiente-Echeverría F; Soto-Rifo R; Weiskopf D; Grifoni A; Sette A; Zeng G; Meng W; González-Aramundiz JV; Johnson M; Goldblatt D; González PA; Abarca K; Bueno SM; Kalergis AM, 2022. Differences in the immune response elicited by two immunization schedules with an inactivated SARS-CoV-2 vaccine in a randomized phase 3 clinical trial. Elife 11.
Schultz BM; Melo-González F; Duarte LF; Gálvez NMS; Pacheco GA; Soto JA; Berríos-Rojas RV; González LA; Moreno-Tapia D; Rivera-Pérez D; Ríos M; Vázquez Y; Hoppe-Elsholz G; Andrade-Parra CA; Vallejos OP; Piña-Iturbe A; Iturriaga C; Urzua M; Navarrete MS; Rojas Á; Fasce R; Fernández J; Mora J; Ramírez E; Gaete-Argel A; Acevedo ML; Valiente-Echeverría F; Soto-Rifo R; Weiskopf D; Grifoni A; Sette A; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Kalergis AM; Bueno SM, 2022. A Booster Dose of CoronaVac Increases Neutralizing Antibodies and T Cells that Recognize Delta and Omicron Variants of Concern. mBio 13(4):e0142322
Vargas L; Valdivieso N; Tempio F; Simon V; Sauma D; Valenzuela L; Beltrán C; Castillo-Delgado L; Contreras-Benavides X; Acevedo ML; Acevedo J; Gonzalez RI; Valiente-Echeverría F; Soto-Rifo R; Rosemblatt M; Lopez M; Osorio F; Bono MR, 2022. Serological study of CoronaVac vaccine and booster doses in Chile: immunogenicity and persistence of anti-SARS-CoV-2 spike antibodies. BMC Med 20(1):216
Acevedo ML; Gaete-Argel A; Alonso-Palomares L; de Oca MM; Bustamante A; Gaggero A; Paredes F; Cortes CP; Pantano S; Martínez-Valdebenito C; Angulo J; Le Corre N; Ferrés M; Navarrete MA; Valiente-Echeverría F; Soto-Rifo R, 2022. Author Correction: Differential neutralizing antibody responses elicited by CoronaVac and BNT162b2 against SARS-CoV-2 Lambda in Chile. Nat Microbiol 7(6):929
Schultz BM; Melo-González F; Duarte LF; Gálvez NM; Pacheco GA; Soto JA; Berríos-Rojas RV; González LA; Moreno-Tapia D; Rivera-Pérez D; Ríos M; Vázquez Y; Hoppe-Elsholz G; Vallejos OP; Iturriaga C; Urzua M; Navarrete MS; Rojas Á; Fasce R; Fernández J; Mora J; Ramírez E; Gaete-Argel A; Acevedo M; Valiente-Echeverría F; Soto-Rifo R; Weiskopf D; Grifoni A; Sette A; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Kalergis AM; Bueno SM, 2022. A booster dose of an inactivated SARS-CoV-2 vaccine increases neutralizing antibodies and T cells that recognize Delta and Omicron variants of concern. medRxiv.
Acevedo ML; Gaete-Argel A; Alonso-Palomares L; de Oca MM; Bustamante A; Gaggero A; Paredes F; Cortes CP; Pantano S; Martínez-Valdebenito C; Angulo J; Le Corre N; Ferrés M; Navarrete MA; Valiente-Echeverría F; Soto-Rifo R, 2022. Differential neutralizing antibody responses elicited by CoronaVac and BNT162b2 against SARS-CoV-2 Lambda in Chile. Nat Microbiol 7(4):524-529
González-Maldonado P; Alvarenga N; Burgos-Edwards A; Flores-Giubi ME; Barúa JE; Romero-Rodríguez MC; Soto-Rifo R; Valiente-Echeverría F; Langjahr P; Cantero-González G; Sotelo PH, 2022. Screening of Natural Products Inhibitors of SARS-CoV-2 Entry. Molecules 27.
Fuentes-Villalobos F; Garrido JL; Medina MA; Zambrano N; Ross N; Bravo F; Gaete-Argel A; Oyarzún-Arrau A; Amanat F; Soto-Rifo R; Valiente-Echeverría F; Ocampo R; Esveile C; Ferreira L; Cabrera J; Torres V; Rioseco ML; Riquelme R; Barría S; Alvarez R; Pinos Y; Krammer F; Calvo M; Barria MI, 2022. Sustained Antibody-Dependent NK Cell Functions in Mild COVID-19 Outpatients During Convalescence. Front Immunol 13:796481
Pereira-Montecinos C; Toro-Ascuy D; Ananías-Sáez C; Gaete-Argel A; Rojas-Fuentes C; Riquelme-Barrios S; Rojas-Araya B; García-de-Gracia F; Aguilera-Cortés P; Chnaiderman J; Acevedo ML; Valiente-Echeverría F; Soto-Rifo R, 2022. Epitranscriptomic regulation of HIV-1 full-length RNA packaging. Nucleic Acids Res 50(4):2302-2318
Wolff MJ; Acevedo ML; Núñez MA; Lafourcade M; Gaete-Argel A; Soto-Rifo R; Valiente-Echeverría F, 2022. Neutralizing antibody titers elicited by CoronaVac and BNT162b2 vaccines in health care workers with and without prior SARS-CoV-2 infection. J Travel Med 29.
Bueno SM; Abarca K; González PA; Gálvez NMS; Soto JA; Duarte LF; Schultz BM; Pacheco GA; González LA; Vázquez Y; Ríos M; Melo-González F; Rivera-Pérez D; Iturriaga C; Urzúa M; Domínguez A; Andrade CA; Berríos-Rojas RV; Canedo-Marroquín G; Covián C; Moreno-Tapia D; Saavedra F; Vallejos OP; Donato P; Espinoza P; Fuentes D; González M; Guzmán P; Muñoz Venturelli P; Pérez CM; Potin M; Rojas Á; Fasce RA; Fernández J; Mora J; Ramírez E; Gaete-Argel A; Oyarzún-Arrau A; Valiente-Echeverría F; Soto-Rifo R; Weiskopf D; Sette A; Zeng G; Meng W; González-Aramundiz JV; Kalergis AM, 2022. Safety and Immunogenicity of an Inactivated Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine in a Subgroup of Healthy Adults in Chile. Clin Infect Dis 75(1):e792-e804
Bueno SM; Abarca K; González PA; Gálvez NM; Soto JA; Duarte LF; Schultz BM; Pacheco GA; González LA; Vázquez Y; Ríos M; Melo-González F; Rivera-Pérez D; Iturriaga C; Urzúa M; Dominguez A; Andrade CA; Berrios RV; Canedo-Marroquín G; Covián C; Moreno-Tapia D; Saavedra F; Vallejos OP; Donato P; Espinoza P; Fuentes D; González M; Guzmán P; Muñoz-Venturelli P; Pérez CM; Potin M; Rojas A; Fasce R; Fernández J; Mora J; Ramírez E; Gaete-Argel A; Oyarzún-Arrau A; Valiente-Echeverría F; Soto-Rifo R; Weiskopf D; Sette A; Zeng G; Meng W; González-Aramundiz JV; Kalergis AM, 2021. Interim report: Safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy chilean adults in a phase 3 clinical trial. medRxiv.
Escobar A; Reyes-López FE; Acevedo ML; Alonso-Palomares L; Valiente-Echeverría F; Soto-Rifo R; Portillo H; Gatica J; Flores I; Nova-Lamperti E; Barrera-Avalos C; Bono MR; Vargas L; Simon V; Leiva-Salcedo E; Vial C; Hormazabal J; Cortes LJ; Valdés D; Sandino AM; Imarai M; Acuña-Castillo C, 2021. Evaluation of the Immune Response Induced by CoronaVac 28-Day Schedule Vaccination in a Healthy Population Group. Front Immunol 12:766278
Alonso-Palomares LA; Cáceres CJ; Tapia R; Aguilera-Cortés P; Valenzuela S; Valiente-Echeverría F; Soto-Rifo R; Gaggero A; Barriga GP, 2021. Surveillance of seasonal respiratory viruses among Chilean patients during the COVID-19 pandemic. Health Sci Rep 4(4):e433
Figueroa F; Vega-Gibson A; Catrileo J; Gaete-Argel A; Riquelme-Barrios S; Alonso-Palomares LA; Tapia LI; Valiente-Echeverría F; Soto-Rifo R; Acevedo ML, 2021. N(6) -Methyladenosine Negatively Regulates Human Respiratory Syncytial Virus Replication. Front Cell Dev Biol 9:739445
Hernández-Díaz T; Valiente-Echeverría F; Soto-Rifo R, 2021. RNA Helicase DDX3: A Double-Edged Sword for Viral Replication and Immune Signaling. Microorganisms 9.
Lopez-Verges S; Valiente-Echeverría F; Godoy-Faúndez A; Fernandez Rivas D; Urbani B; Berger JJ; Carmona-Mora P, 2021. Call to Action: Supporting Latin American Early Career Researchers on the Quest for Sustainable Development in the Region. Front Res Metr Anal 6:657120
Pietrantoni G; Gaete-Argel A; Herrera-Rojo D; Ibarra-Karmy R; Bustos FJ; Valiente-Echeverría F; Arriagada G, 2021. Dynein Light-Chain Dynlrb2 Is Essential for Murine Leukemia Virus Traffic and Nuclear Entry. J Virol 95(15):e0017021
Peña M; Ampuero M; Garcés C; Gaggero A; García P; Velasquez MS; Luza R; Alvarez P; Paredes F; Acevedo J; Farfán MJ; Solari S; Soto-Rifo R; Valiente-Echeverría F, 2021. Performance of SARS-CoV-2 rapid antigen test compared with real-time RT-PCR in asymptomatic individuals. Int J Infect Dis 107:201-204
Gaete-Argel A; Velásquez F; Márquez CL; Rojas-Araya B; Bueno-Nieto C; Marín-Rojas J; Cuevas-Zúñiga M; Soto-Rifo R; Valiente-Echeverría F, 2021. Tellurite Promotes Stress Granules and Nuclear SG-Like Assembly in Response to Oxidative Stress and DNA Damage. Front Cell Dev Biol 9:622057
Balcells ME; Rojas L; Le Corre N; Martínez-Valdebenito C; Ceballos ME; Ferrés M; Chang M; Vizcaya C; Mondaca S; Huete Á; Castro R; Sarmiento M; Villarroel L; Pizarro A; Ross P; Santander J; Lara B; Ferrada M; Vargas-Salas S; Beltrán-Pavez C; Soto-Rifo R; Valiente-Echeverría F; Caglevic C; Mahave M; Selman C; Gazitúa R; Briones JL; Villarroel-Espindola F; Balmaceda C; Espinoza MA; Pereira J; Nervi B, 2021. Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: A randomized phase II clinical trial. PLoS Med 18(3):e1003415
González-Stegmaier R; Cereceda K; Briones JL; Beltran-Pávez C; Oyarzún-Arrau A; Riquelme-Barrios S; Selman C; Yarad F; Mahave M; Caglevic C; Morales R; Aguirre A; Valiente-Echeverría F; Soto-Rifo R; Marsiglia H; Gazitua R; Villarroel-Espindola F, 2021. Seroconversion and Abundance of IgG Antibodies against S1-RBD of SARS-CoV-2 and Neutralizing Activity in the Chilean Population. J Immunol Res 2021:6680337
Beltrán-Pavez C; Riquelme-Barrios S; Oyarzún-Arrau A; Gaete-Argel A; González-Stegmaier R; Cereceda-Solis K; Aguirre A; Travisany D; Palma-Vejares R; Barriga GP; Gaggero A; Martínez-Valdebenito C; Corre NL; Ferrés M; Balcells ME; Fernandez J; Ramírez E; Villarroel F; Valiente-Echeverría F; Soto-Rifo R, 2021. Insights into neutralizing antibody responses in individuals exposed to SARS-CoV-2 in Chile. Sci Adv 7.
Toro-Ascuy D; Gaete-Argel A; Rojas-Celis V; Valiente-Echeverria F, 2021. In Situ Hybridization-Proximity Ligation Assay (ISH-PLA) to Study the Interaction of HIV-1 RNA and Remodeling Proteins. Methods Mol Biol 2209:307-319
García-de-Gracia F; Gaete-Argel A; Riquelme-Barrios S; Pereira-Montecinos C; Rojas-Araya B; Aguilera P; Oyarzún-Arrau A; Rojas-Fuentes C; Acevedo ML; Chnaiderman J; Valiente-Echeverría F; Toro-Ascuy D; Soto-Rifo R, 2021. CBP80/20-dependent translation initiation factor (CTIF) inhibits HIV-1 Gag synthesis by targeting the function of the viral protein Rev. RNA Biol 18(5):745-758
Beltrán-Pavez C; Alonso-Palomares LA; Valiente-Echeverría F; Gaggero A; Soto-Rifo R; Barriga GP, 2021. Accuracy of a RT-qPCR SARS-CoV-2 detection assay without prior RNA extraction. J Virol Methods 287:113969
Velásquez F; Marín-Rojas J; Soto-Rifo R; Torres A; Del Canto F; Valiente-Echeverría F, 2020. Escherichia coli HS and Enterotoxigenic Escherichia coli Hinder Stress Granule Assembly. Microorganisms 9.
Oyarzún-Arrau A; Alonso-Palomares L; Valiente-Echeverría F; Osorio F; Soto-Rifo R, 2020. Crosstalk between RNA Metabolism and Cellular Stress Responses during Zika Virus Replication. Pathogens 9.
Gaete-Argel A; Márquez CL; Barriga GP; Soto-Rifo R; Valiente-Echeverría F, 2019. Strategies for Success. Viral Infections and Membraneless Organelles. Front Cell Infect Microbiol 9:336
Rojas-Celis V; Valiente-Echeverría F; Soto-Rifo R; Toro-Ascuy D, 2019. New Challenges of HIV-1 Infection: How HIV-1 Attacks and Resides in the Central Nervous System. Cells 8.
Toro-Ascuy D; Rojas-Araya B; García-de-Gracia F; Rojas-Fuentes C; Pereira-Montecinos C; Gaete-Argel A; Valiente-Echeverría F; Ohlmann T; Soto-Rifo R, 2018. A Rev-CBP80-eIF4AI complex drives Gag synthesis from the HIV-1 unspliced mRNA. Nucleic Acids Res 46(21):11539-11552
Riquelme-Barrios S; Pereira-Montecinos C; Valiente-Echeverría F; Soto-Rifo R, 2018. Emerging Roles of N(6)-Methyladenosine on HIV-1 RNA Metabolism and Viral Replication. Front Microbiol 9:576
Cinti A; Le Sage V; Milev MP; Valiente-Echeverría F; Crossie C; Miron MJ; Panté N; Olivier M; Mouland AJ, 2017. HIV-1 enhances mTORC1 activity and repositions lysosomes to the periphery by co-opting Rag GTPases. Sci Rep 7(1):5515
Rojas-Mancilla E; Oyarce A; Verdugo V; Morales-Verdejo C; Echeverria C; Velásquez F; Chnaiderman J; Valiente-Echeverría F; Ramirez-Tagle R, 2017. The [Mo₆Cl(14)](2-) Cluster is Biologically Secure and Has Anti-Rotavirus Activity In Vitro. Molecules 22.
Pereira-Montecinos C; Valiente-Echeverría F; Soto-Rifo R, 2017. Epitranscriptomic regulation of viral replication. Biochim Biophys Acta Gene Regul Mech 1860(4):460-471
Toro-Ascuy D; Rojas-Araya B; Valiente-Echeverría F; Soto-Rifo R, 2016. Interactions between the HIV-1 Unspliced mRNA and Host mRNA Decay Machineries. Viruses 8.
Poblete-Durán N; Prades-Pérez Y; Vera-Otarola J; Soto-Rifo R; Valiente-Echeverría F, 2016. Who Regulates Whom? An Overview of RNA Granules and Viral Infections. Viruses 8.
Fröhlich A; Rojas-Araya B; Pereira-Montecinos C; Dellarossa A; Toro-Ascuy D; Prades-Pérez Y; García-de-Gracia F; Garcés-Alday A; Rubilar PS; Valiente-Echeverría F; Ohlmann T; Soto-Rifo R, 2016. DEAD-box RNA helicase DDX3 connects CRM1-dependent nuclear export and translation of the HIV-1 unspliced mRNA through its N-terminal domain. Biochim Biophys Acta 1859(5):719-30
Le Sage V; Cinti A; Valiente-Echeverría F; Mouland AJ, 2015. Proteomic analysis of HIV-1 Gag interacting partners using proximity-dependent biotinylation. Virol J 12:138
Valiente-Echeverría F; Hermoso MA; Soto-Rifo R, 2015. RNA helicase DDX3: at the crossroad of viral replication and antiviral immunity. Rev Med Virol 25(5):286-99
Soto-Rifo R; Valiente-Echeverria F; Rubilar PS; Garcia-de-Gracia F; Ricci EP; Limousin T; Décimo D; Mouland AJ; Ohlmann T, 2014. HIV-2 genomic RNA accumulates in stress granules in the absence of active translation. Nucleic Acids Res 42(20):12861-75
Valiente-Echeverría F; Melnychuk L; Vyboh K; Ajamian L; Gallouzi IE; Bernard N; Mouland AJ, 2014. eEF2 and Ras-GAP SH3 domain-binding protein (G3BP1) modulate stress granule assembly during HIV-1 infection. Nat Commun 5:4819
Le Sage V; Mouland AJ; Valiente-Echeverría F, 2014. Roles of HIV-1 capsid in viral replication and immune evasion. Virus Res 193:116-29
Gordon H; Ajamian L; Valiente-Echeverrìa F; Lévesque K; Rigby WF; Mouland AJ, 2013. Depletion of hnRNP A2/B1 overrides the nuclear retention of the HIV-1 genomic RNA. RNA Biol 10(11):1714-25
Monette A; Valiente-Echeverría F; Rivero M; Cohen ÉA; Lopez-Lastra M; Mouland AJ, 2013. Dual mechanisms of translation initiation of the full-length HIV-1 mRNA contribute to gag synthesis. PLoS One 8(7):e68108
Valiente-Echeverría F; Vallejos M; Monette A; Pino K; Letelier A; Huidobro-Toro JP; Mouland AJ; López-Lastra M, 2013. A cis-acting element present within the Gag open reading frame negatively impacts on the activity of the HIV-1 IRES. PLoS One 8(2):e56962
López J; Abarca K; Mundaca MI; Caballero C; Valiente-Echeverría F, 2012. [Molecular identification of Ehrlichia canis in a dog from Arica, Chile]. Rev Chilena Infectol 29(5):527-30
López J; Valiente-Echeverría F; Carrasco M; Mercado R; Abarca K, 2012. [Morphological and molecular identification of canine filariae in a semi-rural district of the Metropolitan Region in Chile]. Rev Chilena Infectol 29(3):248-89
Valiente-Echeverría F; Melnychuk L; Mouland AJ, 2012. Viral modulation of stress granules. Virus Res 169(2):430-7
Flores C JC; Vizcaya A C; Araos B R; Montecinos P L; Godoy M P; Valiente-Echeverría F; Perret P C; Valenzuela C P; Hirsch B T; Ferrés G M, 2011. [Human bocavirus in Chile: clinical characteristics and epidemiological profile in children with acute respiratory tract infections]. Rev Chilena Infectol 28(6):504-11
Vallejos M; Deforges J; Plank TD; Letelier A; Ramdohr P; Abraham CG; Valiente-Echeverría F; Kieft JS; Sargueil B; López-Lastra M, 2011. Activity of the human immunodeficiency virus type 1 cell cycle-dependent internal ribosomal entry site is modulated by IRES trans-acting factors. Nucleic Acids Res 39(14):6186-200
López-Lastra M; Ramdohr P; Letelier A; Vallejos M; Vera-Otarola J; Valiente-Echeverría F, 2010. Translation initiation of viral mRNAs. Rev Med Virol 20(3):177-95
Vallejos M; Ramdohr P; Valiente-Echeverría F; Tapia K; Rodriguez FE; Lowy F; Huidobro-Toro JP; Dangerfield JA; López-Lastra M, 2010. The 5'-untranslated region of the mouse mammary tumor virus mRNA exhibits cap-independent translation initiation. Nucleic Acids Res 38(2):618-32
Rivas-Aravena A; Ramdohr P; Vallejos M; Valiente-Echeverría F; Dormoy-Raclet V; Rodríguez F; Pino K; Holzmann C; Huidobro-Toro JP; Gallouzi IE; López-Lastra M, 2009. The Elav-like protein HuR exerts translational control of viral internal ribosome entry sites. Virology 392(2):178-85
Abarca K; López J; Perret C; Guerrero J; Godoy P; Veloz A; Valiente-Echeverría F; León U; Gutjahr C; Azócar T, 2007. Anaplasma platys in dogs, Chile. Emerg Infect Dis 13(9):1392-5
.